Heart transplantation is the final life-saving therapeutic strategy for many end-stage heart diseases. Long-term immunosuppressive regimens are needed to prevent allograft rejection. Mesenchymal stromal cells (MSCs) have been shown as immunomodulatory therapy for organ transplantation. However, the effect of dose and timing of MSC treatment on heart transplantation has not yet been examined. In this study, we infused three doses (1 × 106, 2 × 106, or 5 × 106 cells) of human MSCs (hMSCs) to the recipient BALB/c mice before (7 days or 24 h) or after (24 h) receiving C57BL/6 cardiac transplants. We found that infusion of high dose hMSCs (5 × 106) at 24 h post-transplantation significantly prolonged the survival time of cardiac grafts. To delineate the underlying mechanism, grafts, spleens, and draining lymph nodes were harvested for analysis. Dose-dependent effect of hMSC treatment was shown in: (1) alleviation of International Society of Heart and Lung Transplantation (ISHLT) score in grafts; (2) reduction of the population of CD4+ and CD8+ T cells; (3) increase of regulatory T (Treg) cells; (4) and decrease of serum levels of inflammatory cytokines and donor-specific antibodies. Taken together, we showed timing critical and dose-dependent immunomodulatory effects of hMSC treatment against acute allograft rejection in a mouse model of heart transplantation.
Get full access to this article
View all access options for this article.
References
1.
MetraM and TeerlinkJR. (2017). Heart failure. Lancet, 390:1981–1995.
2.
SavareseG and LundLH. (2017). Global public health burden of heart failure. Card Fail Rev, 3:7–11.
3.
BhagraSK, PettitS and ParameshwarJ. (2019). Cardiac transplantation: indications, eligibility and current outcomes. Heart, 105:252–260.
4.
SoderlundC and RadegranG. (2015). Immunosuppressive therapies after heart transplantation—the balance between under- and over-immunosuppression. Transplant Rev (Orlando), 29:181–189.
5.
PotenaL, ZuckermannA, BarberiniF and Aliabadi-ZuckermannA. (2018). Complications of cardiac transplantation. Curr Cardiol Rep, 20:73.
6.
GarakaniR and SaidiRF. (2017). Recent progress in cell therapy in solid organ transplantation. Int J Organ Transplant Med, 8:125–131.
7.
FitzsimmonsREB, MazurekMS, SoosA and SimmonsCA. (2018). Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. Stem Cells Int, 2018:8031718.
8.
Roemeling-van RhijnM, WeimarW and HoogduijnMJ. (2012). Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant, 17:55–62.
9.
DahlkeMH, HoogduijnM, EggenhoferE, PoppFC, RennerP, SlowikP, RosenauerA, PisoP, GeisslerEK, et al. (2009). Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation, 88:614–619.
10.
SoederY, LossM, JohnsonCL, HutchinsonJA, HaarerJ, AhrensN, OffnerR, DeansRJ, Van BokkelenG, et al. (2015). First-in-human case study: multipotent adult progenitor cells for immunomodulation after liver transplantation. Stem Cells Transl Med, 4:899–904.
11.
GeW, JiangJ, BarojaML, ArpJ, ZassokoR, LiuW, BartholomewA, GarciaB and WangH. (2009). Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant, 9:1760–1772.
12.
EggenhoferE, RennerP, SoederY, PoppFC, HoogduijnMJ, GeisslerEK, SchlittHJ and DahlkeMH. (2011). Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol, 25:141–147.
13.
PoppFC, EggenhoferE, RennerP, SlowikP, LangSA, KasparH, GeisslerEK, PisoP, SchlittHJ and DahlkeMH. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol, 20:55–60.
14.
TanJ, WuW, XuX, LiaoL, ZhengF, MessingerS, SunX, ChenJ, YangS, et al. (2012). Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA, 307:1169–1177.
15.
WengJY, DuX, GengSX, PengYW, WangZ, LuZS, WuSJ, LuoCW, GuoR, et al. (2010). Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant, 45:1732–1740.
16.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
17.
MacmillanML, BlazarBR, DeForTE and WagnerJE. (2009). Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant, 43:447–454.
GalipeauJ and SensebeL. (2018). Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell, 22:824–833.
20.
ColvinMM, CookJL, ChangP, FrancisG, HsuDT, KiernanMS, KobashigawaJA, LindenfeldJ, MasriSC, et al. (2015). Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation, 131:1608–1639.
21.
MillingtonTM and MadsenJC. (2010). Innate immunity and cardiac allograft rejection. Kidney Int Suppl, 78:S18–S21.
22.
BharatA and MohanakumarT. (2017). Immune responses to tissue-restricted nonmajor histocompatibility complex antigens in allograft rejection. J Immunol Res, 2017:6312514.
23.
PodestaMA, RemuzziG and CasiraghiF. (2019). Mesenchymal stromal cells for transplant tolerance. Front Immunol, 10:1287.
24.
KaundalU, BagaiU and RakhaA. (2018). Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation. J Transl Med, 16:31.
25.
BenvenutoF, FerrariS, GerdoniE, GualandiF, FrassoniF, PistoiaV, MancardiG and UccelliA. (2007). Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells, 25:1753–1760.
26.
GrohME, MaitraB, SzekelyE and KocON. (2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol, 33:928–934.
27.
ZhangB, LiuR, ShiD, LiuX, ChenY, DouX, ZhuX, LuC, LiangW, et al. (2009). Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood, 113:46–57.
28.
MaccarioR, PodestaM, MorettaA, CometaA, ComoliP, MontagnaD, DaudtL, IbaticiA, PiaggioG, et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 90:516–525.
29.
ZhangAX, YuWH, MaBF, YuXB, MaoFF, LiuW, ZhangJQ, ZhangXM, LiSN, et al. (2007). Proteomic identification of differently expressed proteins responsible for osteoblast differentiation from human mesenchymal stem cells. Mol Cell Biochem, 304:167–179.
30.
YuW, ChenZ, ZhangJ, ZhangL, KeH, HuangL, PengY, ZhangX, LiS, LahnBT and XiangAP. (2008). Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol Cell Biochem, 310:11–18.
31.
MatsuuraA, AbeT and YasuuraK. (1991). Simplified mouse cervical heart transplantation using a cuff technique. Transplantation, 51:896–898.
32.
BillinghamME, CaryNR, HammondME, KemnitzJ, MarboeC, McCallisterHA, SnovarDC, WintersGL and ZerbeA. (1990). A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant, 9:587–593.
33.
WintersGL, MarboeCC and BillinghamME. (1998). The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant, 17:754–760.
34.
WoodKJ and GotoR. (2012). Mechanisms of rejection: current perspectives. Transplantation, 93:1–10.
35.
SiuJHY, SurendrakumarV, RichardsJA and PettigrewGJ. (2018). T cell allorecognition pathways in solid organ transplantation. Front Immunol, 9:2548.
36.
VignaliDA, CollisonLW and WorkmanCJ. (2008). How regulatory T cells work. Nat Rev Immunol, 8:523–532.
37.
CasiraghiF, AzzolliniN, CassisP, ImbertiB, MorigiM, CuginiD, CavinatoRA, TodeschiniM, SoliniS, et al. (2008). Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol, 181:3933–3946.
38.
BartenMJ, SchulzU, Beiras-FernandezA, Berchtold-HerzM, BoekenU, GarbadeJ, HirtS, RichterM, RuhpawarA, et al. (2018). The clinical impact of donor-specific antibodies in heart transplantation. Transplant Rev (Orlando), 32:207–217.
39.
FloreaV, RiegerAC, DiFedeDL, El-KhorazatyJ, NatsumedaM, BanerjeeMN, TompkinsBA, KhanA, SchulmanIH, et al. (2017). Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study). Circ Res, 121:1279–1290.
40.
MullerP, LemckeH and DavidR. (2018). Stem cell therapy in heart diseases—cell types, mechanisms and improvement strategies. Cell Physiol Biochem, 48:2607–2655.
41.
WangZ, WangL, SuX, PuJ, JiangM and HeB. (2017). Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Stem Cell Res Ther, 8:21.
42.
ChangYS, ChoiSJ, AhnSY, SungDK, SungSI, YooHS, OhWI and ParkWS. (2013). Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One, 8:e52419.
43.
TanakaE, OgawaY, MukaiT, SatoY, HamazakiT, Nagamura-InoueT, Harada-ShibaM, ShintakuH and TsujiM. (2018). Dose-dependent effect of intravenous administration of human umbilical cord-derived mesenchymal stem cells in neonatal stroke mice. Front Neurol, 9:133.
44.
ChangYS, ChoiSJ, SungDK, KimSY, OhW, YangYS and ParkWS. (2011). Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant, 20:1843–1854.
45.
RaJC, ShinIS, KimSH, KangSK, KangBC, LeeHY, KimYJ, JoJY, YoonEJ, ChoiHJ and KwonE. (2011). Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev, 20:1297–1308.
46.
HoJH, TsengTC, MaWH, OngWK, ChenYF, ChenMH, LinMW, HongCY and LeeOK. (2012). Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta-cell differentiation in streptozocin-induced diabetic mice. Cell Transplant, 21:997–1009.
47.
RichardsonJD, PsaltisPJ, FrostL, PatonS, CarboneA, BertasoAG, NelsonAJ, WongDT, WorthleyMI, et al. (2014). Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy, 16:460–470.
48.
GlennieS, SoeiroI, DysonPJ, LamEW and DazziF. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 105:2821–2827.
49.
BartholomewA, SturgeonC, SiatskasM, FerrerK, McIntoshK, PatilS, HardyW, DevineS, UckerD, et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 30:42–48.
50.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE and DazziF. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101:3722–3729.
51.
LanT, WangL, XuL, JinN, YanG, XiaJ, WangH, ZhuangG, GaoC, et al. (2016). Induced pluripotent stem cells can effectively differentiate into multiple functional lymphocyte lineages in vivo with negligible bias. Stem Cells Dev, 25:462–471.
52.
GoodwinM, SueblinvongV, EisenhauerP, ZiatsNP, LeClairL, PoynterME, SteeleC, RinconM and WeissDJ. (2011). Bone marrow-derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells, 29:1137–1148.
53.
TangQ and VincentiF. (2017). Transplant trials with Tregs: perils and promises. J Clin Invest, 127:2505–2512.
54.
GiulianiM, FleuryM, VernochetA, KetroussiF, ClayD, AzzaroneB, LatailladeJJ and DurrbachA. (2011). Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One, 6:e19988.
55.
BustosML, HuleihelL, MeyerEM, DonnenbergAD, DonnenbergVS, SciurbaJD, MrozL, McVerryBJ, EllisBM, KaminskiN and RojasM. (2013). Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med, 2:884–895.
56.
PengY, ChenX, LiuQ, ZhangX, HuangK, LiuL, LiH, ZhouM, HuangF, et al. (2015). Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia, 29:636–646.
57.
GalleuA, Riffo-VasquezY, TrentoC, LomasC, DolcettiL, CheungTS, von BoninM, BarbieriL, HalaiK, et al. (2017). Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med, 9:eaam7828.
58.
De WitteSFH, LukF, Sierra ParragaJM, GargeshaM, MerinoA, KorevaarSS, ShankarAS, O'FlynnL, EllimanSJ, et al. (2018). Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells, 36:602–615.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
